EGFR and breast cancer: Liposome-based nanocarriers loaded with DOX in combination with erlotinib (ERLO), an EGFR (epidermal growth factor receptor) inhibitor, was significantly able to reduce tumor growth in a xenograft mouse model obtained with the BT-20 human breast cancer cell line, by promoting apoptotic signals and tumor cell death [50].